Mirum Pharmaceuticals Inc. Common Stock (MIRM)
Stock · NASDAQ · Health Care
$80.09as of 10/16/2026
Price chart
Active signals
MIRM Signal Track Record
How signals performed across all stocks →What MIRM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | +5.5% | 65% | September 15, 2026 |
| Bollinger Band Breakout | 26 | -1.9% | 46% | June 18, 2026 |
| Bollinger Band Breakdown | 18 | +4.2% | 61% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -1.2% | 50% | September 14, 2026 |
| Any 20-session window (baseline) | +1.9% | 56% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the Unite…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 433
- Website
- mirumpharma.com/
Fundamentals
- 1-day range
- $81$83.48
- Market cap
- $5.74B
- P/E (trailing)
- —
- P/E (forward)
- -114.43
- EPS (trailing)
- $-14.55
- Dividend yield
- —
- Beta
- 0.75
- Avg. volume
- 730.5K
How Mirum Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
14 analyst ratings
Mirum Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MIRMMirum Pharmaceuticals Inc. Common Stock$80.14▼ 2.73%Market cap $5.74BP/E —$63.23$130
- AMRXAmneal Pharmaceuticals Inc. Class A Common Stock$19.18▼ 0.36%Market cap $5.76BP/E 39.88$9.56$21.18
- TVTXTravere Therapeutics Inc. Common Stock$49.6▼ 6.04%Market cap $5.89BP/E —$22.59$68.73
- PTCTPTC Therapeutics Inc. Common Stock$59.24▼ 2.87%Market cap $5.91BP/E —$58.8$90.87
- KNSAKiniksa Pharmaceuticals International plc Class A Ordinary Shares$78.59▼ 1.69%Market cap $5.97BP/E 77.33$35.2$82.94
- LGNDLigand Pharmaceuticals Incorporated Common Stock$295.54▼ 0.99%Market cap $6.02BP/E 30.38$175.89$326.63
- GRFSGrifols S.A. American Depositary Shares$7.64▲ 1.33%Market cap $5.38BP/E 12.88$8.43$12.15
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals Inc. Common Stock | $5.74B | — | $80.14 | ▼ 2.73% | $63.23$130 |
| AMRX Amneal Pharmaceuticals Inc. Class A Common Stock | $5.76B | 39.88 | $19.18 | ▼ 0.36% | $9.56$21.18 |
| TVTX Travere Therapeutics Inc. Common Stock | $5.89B | — | $49.6 | ▼ 6.04% | $22.59$68.73 |
| PTCT PTC Therapeutics Inc. Common Stock | $5.91B | — | $59.24 | ▼ 2.87% | $58.8$90.87 |
| KNSA Kiniksa Pharmaceuticals International plc Class A Ordinary Shares | $5.97B | 77.33 | $78.59 | ▼ 1.69% | $35.2$82.94 |
| LGND Ligand Pharmaceuticals Incorporated Common Stock | $6.02B | 30.38 | $295.54 | ▼ 0.99% | $175.89$326.63 |
| GRFS Grifols S.A. American Depositary Shares | $5.38B | 12.88 | $7.64 | ▲ 1.33% | $8.43$12.15 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $156benzinga · 10/15/2026
- RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $155Benzinga · 10/8/2026
- Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta StudyYahoo · 10/2/2026
- PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approvalYahoo · 9/30/2026
- Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $160Benzinga · 9/29/2026
- Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDVYahoo · 9/29/2026
- Is Mirum Pharmaceuticals (MIRM) Undervalued On New Brelo Vitug Trial Data?Yahoo · 9/29/2026
- Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $130Benzinga · 9/29/2026
- MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder TherapyYahoo · 9/28/2026
Insider Activity
Insider Actions →- Christopher Peetz · October 6, 2026 · Option Exercise6.9K @ $15.87
- Christopher Peetz · October 6, 2026 · Option Exercise5.3K @ $19.19
- Eric Bjerkholt · September 14, 2026 · Sale9.9K @ $98.37
- Eric Bjerkholt · September 11, 2026 · Option Exercise18.3K
- Howe Jolanda · September 2, 2026 · Sale658 @ $100
- Christopher Peetz · September 1, 2026 · Option Exercise30.0K @ $2.94
- Christopher Peetz · September 1, 2026 · Sale21.7K @ $98.91
- Christopher Peetz · September 1, 2026 · Sale8.3K @ $98.08
- Howe Jolanda · August 18, 2026 · Option Exercise40.0K @ $6.27
- Howe Jolanda · August 18, 2026 · Sale40.0K @ $100
- Eric Bjerkholt · August 11, 2026 · Sale6.0K @ $99.9
- Christopher Peetz · August 10, 2026 · Option Exercise20.0K @ $2.94
- Christopher Peetz · August 10, 2026 · Sale2.3K @ $100.14
- Christopher Peetz · August 10, 2026 · Sale6.0K @ $99.25
- Christopher Peetz · August 10, 2026 · Sale11.7K @ $98.51
Institutional Ownership
March 31, 2026
- Total shares held
- 66.48M
- Total value held
- $5.89B
- Institutional holders
- 304
- Unknown7.68M
- Unknown6.95M
- Unknown3.85M
- Unknown2.41M
- Unknown1.97M
- Unknown1.94M
- Unknown1.72M
- Unknown1.58M
- Unknown1.41M
- Unknown1.33M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta
Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta. Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.